Betta Pharmaceuticals (300558.SZ): There are currently no clinical trials of PD-L1 small molecule combined with befotinib
Gelonghui, May 16 | Betta Pharmaceutical (300558.SZ) said on the investor interactive platform that the company is currently not conducting clinical trials of PD-L1 small molecules combined with befotinib.
Betta Pharmaceutical (300558.SZ): Currently, the company's Dream Factory Phase III construction plan
Gelonghui, May 10 | Betta Pharmaceutical (300558.SZ) said on the investor interactive platform that the company is currently planning to build Phase III of the company's Dream Factory. Please pay attention to the company's regular reports on the details of the company's fixed assets and projects under construction.
Betta Pharmaceuticals (300558.SZ): No drugs have been marketed or research projects for stem cell therapy or cancer vaccines
Gelonghui, May 10 | Betta Pharmaceutical (300558.SZ) said on the investor interactive platform that at present, the company has not launched drugs or established research projects related to stem cell therapy or tumor vaccines. In terms of immunotherapy, the company's R&D pipeline includes a bispecific IgG1 subtype humanized antibody BPB-101 double antibody injection project with three functions, and an oral small-molecule PD-L1 inhibitor BPI-371153 project.
Betta Pharmaceutical (300558.SZ): Currently, the BPI-16350 project second-line indicated drug registration review and approval process is in progress
Gelonghui, May 10 | Betta Pharmaceutical (300558.SZ) said on the investor interactive platform that submitting a drug registration application with second-tier indications is a routine plan for the marketing of new drugs. Currently, the BPI-16350 project second-line drug registration review and approval process is in progress. If there are plans to expand indications in the future, the company will promptly announce and disclose them.
Private Companies Among Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) Largest Shareholders, Saw Gain in Holdings Value After Stock Jumped 5.1% Last Week
Key Insights Significant control over Betta Pharmaceuticals by private companies implies that the general public has more power to influence management and governance-related decisions 50% of the bu
Betta Pharmaceutical (300558.SZ): Thebesilil tartrate capsules completed phase III clinical trials and obtained a summary report
Zhitong Finance App News, Betta Pharmaceutical (300558.SZ) issued an announcement. After completing the phase III clinical trial of the company's self-developed project BPI-16350 (tebesilil tartrate capsules), a clinical trial summary report has been obtained through a series of statistical data analysis work. This drug, in combination with fluvirizin, is suitable for patients with locally advanced or advanced recurrent metastatic breast cancer with positive hormone receptor (HR) and negative for human epidermal growth factor receptor 2 (HER2), which progresses after previous endocrine treatment. The study results showed that, based on the researcher's evaluation, the BPI-16350+ fluvir group was previously accepted
Betta Pharmaceuticals (300558.SZ): Currently, there are no stem cell drugs on the market or research projects for diabetes treatment
Gelonghui, April 22 | Betta Pharmaceutical (300558.SZ) said on the investor interactive platform that the company currently has no stem cell drugs on the market or set up research projects to treat diabetes.
Betta Pharmaceuticals (300558.SZ) reported first-quarter results, net profit of 98.1407 million yuan, an increase of 90.95% year-on-year
Betta Pharmaceuticals (300558.SZ) released its report for the first quarter of 2024, with revenue of 736 million yuan, compared with...
Some Shareholders Feeling Restless Over Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Ratio
With a price-to-earnings (or "P/E") ratio of 45.3x Betta Pharmaceuticals Co., Ltd. (SZSE:300558) may be sending bearish signals at the moment, given that almost half of all companies in China have P/E
Betta Pharmaceuticals (300558.SZ): Currently, there are no stem cell-related drugs on the market or the establishment of research projects
On April 15, Gelonghui | Betta Pharmaceutical (300558.SZ) said on the investor interactive platform that the company currently has no stem cell-related drugs on the market or set up research projects. In May 2023, the company invested in the introduction of the CFT8919 project, a modified BiDAC (bifunctional protein degrading agent) with oral bioavailability, which has good activity and selectivity for carrying EGFR L858R mutations. Currently, the development of this new drug is progressing according to plan.
Betta Pharmaceuticals (300558.SZ): Befotinib has not conducted clinical studies on indications related to 20 exon insertion
Glonghui, April 9丨An investor asked Betta Pharmaceuticals (300558.SZ) on the investor interactive platform, “Has your company carried out domestic clinical research on 20 exon insertion indications?” The company replied that currently, befotinib has not conducted clinical studies on indications related to 20 exon insertion.
Betta Pharmaceuticals (300558.SZ): It already has five marketed products: Kaimena, Bemena, Saimena, Vomena, and Beantin
Gelonghui, April 9 | Betta Pharmaceutical (300558.SZ) said on the investor interactive platform that the company already has five listed products: Kaimena, Bemena, Saimena, Vomena, and Beantin. Each product has its own launch point and life cycle. The company formulates targeted promotion strategies for each product and promotes implementation. Since Kaimena was launched, indication expansion has continued to extend the product life cycle; Bemena was listed in November 2020 and continues to contribute to the company's revenue growth with clinically differentiated data advantages; Beantin went public in November 2021, through professional promotion and accelerated implementation
Betta Pharmaceuticals (300558.SZ): BPI-52005 tablets obtained clinical trial approval notice
Gelonghui, March 20 | Betta Pharmaceutical (300558.SZ) announced that today, Betta Pharmaceutical Co., Ltd. received the “Drug Clinical Trial Approval Notice” (Notice No.: 2024LP00681, 2024LP00682, 2024LP00683) issued by the National Drug Administration (“NMPA”), and the BPI-520105 drug clinical trial application declared by the company has been approved by the NMPA.
Does The Market Have A Low Tolerance For Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) Mixed Fundamentals?
Betta Pharmaceuticals (SZSE:300558) has had a rough three months with its share price down 12%. It seems that the market might have completely ignored the positive aspects of the company's fundament
Betta Pharmaceuticals (300558.SZ): The company currently has no growth hormone-related drugs on the market or the establishment of research projects
On March 13, Gelonghui | Betta Pharmaceutical (300558.SZ) said on the investor interactive platform that the company currently has no drugs related to growth hormone on the market or set up research projects.
Betta Pharmaceuticals (300558.SZ): No drugs have been marketed or research projects for oncology vaccines have been established
Gelonghui March 1 | Betta Pharmaceutical (300558.SZ) said on the investor interactive platform that at present, the company has no drugs on the market or set up research projects for cancer vaccines. In terms of immunotherapy, the R&D pipeline includes a bispecific IgG1 subtype humanized antibody BPB-101 double antibody injection project with three functions, and an oral small-molecule PD-L1 inhibitor BPI-371153 project.
Betta Pharmaceuticals' (SZSE:300558) Earnings Have Declined Over Three Years, Contributing to Shareholders 62% Loss
Investing in stocks inevitably means buying into some companies that perform poorly. But the long term shareholders of Betta Pharmaceuticals Co., Ltd. (SZSE:300558) have had an unfortunate run in the
Betta Pharmaceutical (300558.SZ): As of January 31, 2024, the total number of A-share common shareholders of the company was 25,983
Gelonghui, February 2 | Betta Pharmaceutical (300558.SZ) said on the investor interactive platform that as of January 31, 2024, the total number of A-share common shareholders of the company was 25,983.
Betta Pharmaceuticals (300558.SZ): Currently, there are no drugs on the market or research projects for fever
Gelonghui, February 2 | Betta Pharmaceutical (300558.SZ) said on the investor interactive platform that the company mainly develops innovative drugs in the field of oncology around unmet treatment needs. Currently, there are no drugs marketed or research projects for fever.
These 4 Measures Indicate That Betta Pharmaceuticals (SZSE:300558) Is Using Debt Extensively
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
No Data